Compare Novavax Inc (NVAX) vs iShares 20 Plus Year Treasury Bond ETF (TLT) Price & Performance

Novavax IncTrade

iShares 20 Plus Year Treasury Bond ETFTrade

Price performance (Past 24H)

Key statistics

Novavax Inc vs iShares 20 Plus Year Treasury Bond ETF — how do they compare? Novavax Inc trades at $9.9 (market cap $1.68B), while iShares 20 Plus Year Treasury Bond ETF trades at $81.48. The key difference: Novavax Inc is trading nearer its 52-week high, iShares 20 Plus Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.

	NVAX	TLT
Market Cap	$1.68B	—
Sector	Health	—
52-Week High	$11.19	$92.06
52-Week Low	$6.22	$81.35
Enterprise Value	$1.26B	—

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Novavax Inc

Novavax (NVAX) trades at $10.19, down 0.29% today, with a bullish technical signal from moving averages but overbought RSI levels. Recent Q2 2026 earnings beat expectations, and the company raised its 2026 revenue outlook. Key developments include regulatory approvals for its updated COVID-19 vaccine in the U.S., EU, and Japan for the 2026-2027 season, alongside ongoing partnerships with Sanofi and Pfizer.

The outlook is mixed: strong analyst buy ratings (73.9%) and partnership milestones offer upside, but negative net income margins and cash flow challenges pose risks. Investors should weigh the potential from vaccine demand and adjuvant platform royalties against financial sustainability concerns and competitive pressures in the biotech sector.

iShares 20 Plus Year Treasury Bond ETF

TLT, the iShares 20+ Year Treasury Bond ETF, trades at $82.2 with minimal daily change. Technical signals are bearish, with moving averages indicating selling pressure and oscillators neutral. Recent Treasury buyback announcements and rising global bond yields create a volatile backdrop. The ETF continues its dividend distributions, with recent payments around $0.32 per share.

Outlook remains cautious amid rising interest rate expectations and inflation concerns. Investment opportunity exists for long-term income seekers, but risks include further yield increases and potential large-scale Treasury selling by institutional investors like Norway's sovereign fund.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

NVAX

Novavax shifts focus from COVID vaccine sales to licensing its vaccine tech globally.Seeking Alpha · 16 hours agoBullish View details →

TLT

Long-term U.S. Treasuries post worst decade since Great Depression, signaling a rare buying opportunity.24/7 Wall Street · 1 day agoBullish Investor favors long-term bonds amid economic slowdown and potential inflation drop due to AI cost savings.Seeking Alpha · 2 days agoBullish Norway's sovereign fund plans to sell $80B in long-term U.S. Treasuries, raising concerns for TLT ETF holders.24/7 Wall Street · 2 days agoBearish View details →

About Novavax Inc

Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.

About iShares 20 Plus Year Treasury Bond ETF

The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index. The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity greater than or equal to twenty years.